• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alcon Inc. Ordinary Shares (NY:ALC)

    82.09 +1.44 (+1.79%)
    Streaming Delayed Price Updated: 10:16 AM EST, Jan 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alcon Inc. Ordinary Shares

    < Previous 1 2 3 4 Next >
    News headline image
    Alcon to Present at 2026 Annual J.P. Morgan Healthcare Conference
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces Amended Merger Agreement with STAAR Surgical
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
    From STAAR Surgical Company
    Via Business Wire
    News headline image
    Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
    From Alcon Inc. Investors and STAAR Surgical Company
    Via Business Wire
    News headline image
    STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
    From STAAR Surgical Company
    Via Business Wire
    News headline image
    Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon to Present at 2025 Baird Global Healthcare Conference
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSE - WOW), BankFinancial Corporation (Nasdaq - BFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Alcon Agrees to Acquire STAAR Surgical
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
    EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces Results of 2025 Annual General Meeting
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Publishes Agenda for 2025 Annual General Meeting
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Agrees to Acquire LENSAR, Inc.
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon to Host 2025 Capital Markets Day
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters
    From Alcon Canada
    Via Business Wire
    News headline image
    Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
    From Alcon Inc. Investors
    Via Business Wire
    News headline image
    Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
    From Alcon Inc. Investors
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.